enGene is a biotechnology company develops treatment for mucosal diseases through inducing therapeutic proteins of harmful proteins.
enGene is a developer of a mucosal immunotherapy platform designed to treat inflammatory bowel disease and diabetes. The company's mucosal immunotherapy platform has developed a flexible nucleotide delivery technology targeting mucosal tissues to treat numerous prevalent, chronic diseases via the induction or suppression of protein expression levels, enabling physicians and doctors to regenerate physiologic, meal-regulated insulin secretion from the gut of subjects with diabetes.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jan 26, 2015 | Series B | $11.50M | 1 | — | — | Detail |
Mar 17, 2008 | Series A | $6.40M | 1 | Adams, Harkness & Hill Technology Ventures | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Adams, Harkness & Hill Technology Ventures | Yes | Series A |
Inbio Ventures | — | Series B |